Showing 201 - 220 results of 258 for search '"hematologic malignancies"', query time: 0.05s Refine Results
  1. 201

    Systematic Characterization of Splicing Dysregulation in Pan Solid Tumor Transcriptome by Jingru Sui, Dan Guo, Xiao Wen, Lei Zhou, Yue Huang, Haoyu Yu, Jinyu Chen, Zhaoqi Liu

    Published 2025-01-01
    “…Abstract Splicing dysregulation arising from spliceosomal mutations contributes to disease progression and treatment resistance, mostly in hematologic malignancy. Whereas spliceosomal mutations are less common in solid tumors, splicing disorders are pervasive and proven to promote tumorigenesis. …”
    Get full text
    Article
  2. 202
  3. 203

    The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen by Quane Zhang, Yifan Wang, Wenting Shi, Yue Chen, Zhengmei He, Liang Yu, Chunling Wang

    Published 2025-01-01
    “…Abstract Multiple myeloma (MM) is the second most common hematological malignancy. Previous studies have validated the prognostic significance of the platelet-to-lymphocyte ratio (PLR) in patients with certain solid tumors. …”
    Get full text
    Article
  4. 204

    Concordance of Peripheral Blood and Bone Marrow Next-Generation Sequencing in Hematologic Neoplasms by Chayanit Jumniensuk, Alexander Nobori, Thomas Lee, T. Niroshi Senaratne, Dinesh Rao, Sheeja Pullarkat

    Published 2022-01-01
    “…We evaluated patients who had NGS for presumed hematologic malignancy performed on peripheral blood and bone marrow within a 1-year interval of each other. …”
    Get full text
    Article
  5. 205

    Presentation of disseminated neuroblastoma mimicking Bell’s palsy: a case report by Shamaali Gunawardana, Geerthana Jogaprajahpan, Kavinda Dayasiri

    Published 2025-01-01
    “…Conclusion Facial nerve palsy is well recognized to have a myriad of underlying etiologies, including hematological malignancies, solid tumors, and paraneoplastic syndromes. …”
    Get full text
    Article
  6. 206

    Pooled screening for CAR function identifies novel IL-13Rα2-targeted CARs for treatment of glioblastoma by Douglas A Lauffenburger, Khloe S Gordon, Caleb R Perez, Andrea Garmilla, Maxine S Y Lam, Joey J Y Aw, Anisha Datta, Andrea Pavesi, Michael E Birnbaum

    Published 2025-02-01
    “…It also showed significantly improved persistence and comparable tumor control in a microphysiological human in vitro model and a xenograft model of human glioblastoma, but also demonstrated increased off-target recognition of IL-13Rα1.Conclusion Taken together, this work demonstrates the utility of extending CARPOOL to diseases beyond hematological malignancies and represents the largest exploration of signaling combinations in human primary cells to date.…”
    Get full text
    Article
  7. 207

    Primary Bone Marrow B-Cell Lymphoma Undetected by Multiple Imaging Modalities That Initially Presented with Hypercalcemia by Jin Sae Yoo, Juwon Kim, Hyeong Ju Kwon, Jung Soo Lim

    Published 2018-01-01
    “…A bone marrow biopsy was performed to identify any hidden hematologic malignancy. As a result, the pathology of bone marrow confirmed the presence of atypical lymphocytes that stained positive for the CD20 marker, which is consistent with BCL involving the bone marrow. …”
    Get full text
    Article
  8. 208

    Listeria monocytogenes and Staphylococcus aureus coinfection in a patient with multiple myeloma: Case report by Roberta Vaikutyte-Ramanauskiene, Danguole Vaznaisiene

    Published 2025-01-01
    “…Conclusion: In conclusion, this case emphasizes the intersection of hematological malignancy, chemotherapy-related immunosuppression, and subsequent severe disseminated bacterial infections and coinfections. …”
    Get full text
    Article
  9. 209

    ANTIBIOTIC LOCK THERAPY FOR PORT CATHETER-RELATED INFECTIONS OF CHILDREN WITH ACUTE LEUKEMIA by Burçin Kurtipek, Ayça Koca Yozgat, Saliha Kanık Yüksek, Dilek Kaçar, Turan Bayhan, Dilek Gürlek Gökçebay, Aslınur Özkaya Parlak, Neşe Yaralı

    Published 2024-08-01
    “… Background: Port catheters facilitate the administration of chemotherapy, antibiotics, blood products, fluid and parenteral nutritional support to pediatric patients with hematological malignancies. However, as its use has become widespread, local, and systemic catheter-related infections have emerged as important causes of morbidity and mortality. …”
    Get full text
    Article
  10. 210

    Graft-Versus-Host Disease Sustains Coagulation Activity for two Years After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation by Satu Långström MD, PhD, Minna Koskenvuo MD, PhD, Pasi Huttunen MD, PhD, Riitta Lassila MD, PhD, Mervi Taskinen MD, PhD, Susanna Ranta MD, PhD, Markku Heikinheimo MD, PhD, Anne Mäkipernaa MD, PhD

    Published 2025-02-01
    “…Aim To evaluate the longitudinal coagulation profile after allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with hematological malignancies. Methods Several coagulation variables were measured at predetermined time points for two years after HSCT in 30 pediatric patients. …”
    Get full text
    Article
  11. 211

    Impact of leukemia subtype and demographics on patient quality of life in 76 countries: a cross-sectional study by Sam Salek, Samantha Nier, Zack Pemberton-Whiteley, Tatyana Ionova, Giuseppe Ianni, Giovanni Tripepi, Nick York, Nicole Schroeter, Kathryn Huntley, Michael Rynne, Denis Costello, Lidija Pecova, Esther Natalie Oliva

    Published 2025-01-01
    “…BackgroundDisease-specific factors associated with decreased quality of life (QoL) in patients with leukemia have not been studied in a large-scale, global, observational study.MethodsThis cross-sectional study used the validated Hematological Malignancy Patient Reported Outcomes (HM-PRO) questionnaire to assess the impact of leukemia subtype, age, sex, and years living with the disease on QoL of patients with leukemia.ResultsOverall, 2,628 patients responded: 45.7% had chronic lymphocytic leukemia (CLL), 34.0% had chronic myeloid leukemia (CML), 11.8% had acute myeloid leukemia (AML), and 3.5% had acute lymphoblastic leukemia (ALL). …”
    Get full text
    Article
  12. 212
  13. 213

    Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment by Robert Brown, Marco Donia, Simon Turcotte, George Coukos, John Mullinax, Brian Gastman, James C Yang, Michael T Lotze, John B A G Haanen, Inge Marie Svane, Stephanie L Goff, Vernon K Sondak, Maartje W Rohaan, Michal Besser, Benjamin Creelan

    Published 2025-01-01
    “…Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. …”
    Get full text
    Article
  14. 214

    Antianemic Treatment of Cancer Patients in German Routine Practice: Data from a Prospective Cohort Study—The Tumor Anemia Registry by Tilman Steinmetz, Jan Schröder, Margarete Plath, Hartmut Link, Michèle Vogt, Melanie Frank, Norbert Marschner

    Published 2016-01-01
    “…Patients were followed up for 12 weeks. 63% of the patients had inoperable solid tumors, 22% operable solid tumors, and 15% hematological malignancies. Over 85% received chemotherapy. …”
    Get full text
    Article
  15. 215

    Unveiling the omics tapestry of B-acute lymphoblastic leukemia: bridging genomics, metabolomics, and immunomics by Yin Le, Shicong Zhu, Hongling Peng, Zhihua Wang

    Published 2025-01-01
    “…Abstract Acute B-lymphoblastic leukemia (B-ALL) is a highly heterogeneous hematologic malignancy, characterized by significant molecular differences among patients as the disease progresses. …”
    Get full text
    Article
  16. 216

    Risk Factors and Predictive Model for Disseminated Intravascular Coagulation in Patients with Multiple Myeloma by Rong Bao MM, Mengtong Fan MM, Min Hu MM, Ling Li BD,   Hasichaolu BD

    Published 2025-02-01
    “…Objectives Multiple myeloma (MM) is a hematologic malignancy comprising approximately 10% of all blood cancers. …”
    Get full text
    Article
  17. 217

    Cryo-thermal therapy reshaped the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy by Shicheng Wang, Peng Peng, Junjun Wang, Zelu Zhang, Ping Liu, Lisa X. Xu

    Published 2024-11-01
    “…Abstract Background Adoptive cell therapies (ACT) exhibit excellent efficacy in hematological malignancy. However, its application in solid tumors still has many challenges partly due to the tumor immune microenvironment. …”
    Get full text
    Article
  18. 218

    Determinants of Deescalation Failure in Critically Ill Patients with Sepsis: A Prospective Cohort Study by Nawal Salahuddin, Lama Amer, Mini Joseph, Alya El Hazmi, Hassan Hawa, Khalid Maghrabi

    Published 2016-01-01
    “…On multivariate regression analysis, failure to deescalate was significantly predicted by hematologic malignancy OR 3.3 (95% CI 1.4–7.4) p<0.004, fungal sepsis OR 2.7 (95% CI 1.2–5.8) p=0.011, multidrug resistance OR 2.9 (95% CI 1.4–6.0) p=0.003, baseline serum procalcitonin OR 1.01 (95% CI 1.003–1.016) p=0.002, and SAPS II scores OR 1.01 (95% CI 1.004–1.02) p=0.006. …”
    Get full text
    Article
  19. 219

    Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice by Dai Fukumura, Rakesh K Jain, Jun Ren, Xinyue Dong, Zohreh Amoozgar, Somin Lee, Meenal Datta, Sylvie Roberge, Mark Duquette

    Published 2023-03-01
    “…Chimeric antigen receptor (CAR)-T cells have revolutionized the treatment of multiple types of hematological malignancies, but have shown limited efficacy in patients with glioblastoma (GBM) or other solid tumors. …”
    Get full text
    Article
  20. 220

    Cytogenetically Unrelated Clones in Acute Myeloid Leukemia Showing Different Responses to Chemotherapy by Kohei Kasahara, Masahiro Onozawa, Naohiro Miyashita, Emi Yokohata, Miho Yoshida, Minoru Kanaya, Mizuha Kosugi-Kanaya, Ryo Takemura, Shojiro Takahashi, Junichi Sugita, Akio Shigematsu, Mutsumi Takahata, Shinichi Fujisawa, Daigo Hashimoto, Katsuya Fujimoto, Tomoyuki Endo, Takeshi Kondo, Takanori Teshima

    Published 2016-01-01
    “…Simultaneous onset of cytogenetically unrelated hematological malignancies that each have a different disease status is a rare phenomenon but is important to diagnose for a correct understanding of the disease status and for establishing an appropriate treatment strategy.…”
    Get full text
    Article